US Edition#From Innovation to Impact Optune Lua Gains CE Mark for Metastatic NSCLC Treatment,
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
#From Innovation to Impact Optune Lua Gains CE Mark for Metastatic NSCLC Treatment,
Evolving Cancer Treatment: Optune Lua Receives CE Mark for Advanced NSCLC Therapy' In a significant stride toward the advancement of cancer treatment technologies, Novocure (NASDAQ: NVCR), a global oncology company, has announced the CE (Conformit� Europ�enne) mark approval for Optune Lua. This sophisticated device has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who have experienced disease …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
